ArticleOpen forum infectious diseases2025
Long-term Sequelae in Ebola Virus Disease Survivors Receiving Anti-Ebola Virus Therapies in the Democratic Republic of the Congo: A Prospective Cohort Study.
Article in Open forum infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04409405 (Evaluation and Support to Ebola Virus Disease Cured Patients and Their Contacts in the Democratic Republic of the Congo), which is not on this map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Evaluation and Support to Ebola Virus Disease Cured Patients and Their Contacts in the Democratic Republic of the Congo
Who cites it
3 citing papers in PubMed.
- Bundibugyo virus disease evidence map: a rapid research needs appraisal.EClinicalMedicine · 2026Article
- Platelet-like particles released from Ebola virus-infected megakaryocytic cells behave like virus-like particles.PLoS pathogens · 2026Article
- Donor dependency and pandemic readiness: insights from the 2026 Ebola Bundibugyo outbreak in the East African community.Frontiers in public health · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The 2018-2020 Ebola outbreak in the Democratic Republic of the Congo marked the first major cohort of Ebola survivors treated with advanced therapeutics, including monoclonal antibodies (REGN-EB3, ansuvimab, ZMapp) and remdesivir. This study explored factors influencing long-term sequelae in survivors who received these specific therapies. Methods: A prospective multicenter study enrolled 750 Ebola survivors from the 10th outbreak in the Democratic Republic of the Congo between April and October 2020. Participants were followed for 12 months to assess the recurrence of clinical sequelae according to Weibull and shared frailty models. Results: Of 750 of Ebola survivors, 650 (86.7%) experienced post-Ebola sequalae. The median age of survivors was 32 years and 56.7% were female. Among them, 463 (61.7%) experienced neurologic sequelae, 373 (49.7%) musculoskeletal sequelae, and 288 (38.4%) general sequelae. Globally, these persisted for at least 38 months postdischarge, with slight decreases over time. At enrollment (median time to baseline visit, 330 days after discharge), neurologic sequelae were more frequent in the REGN-EB3 group (hazard ratio, 2.14; 95% CI, 1.28-3.57) as compared with the remdesivir group. Musculoskeletal sequelae were associated with age (1.02; 1.00-1.03), ZMapp treatment (3.17; 1.81-5.56), and acute-phase hemorrhagic symptoms (1.64; 1.14-2.36). Ocular sequelae were associated with age (1.04; 1.02-1.06). Female sex, older age, metabolic comorbidities, and REGN-EB3 therapy were associated with recurrent neurologic and musculoskeletal sequelae. Recurrent ocular sequelae were more frequent in adults (1.02; 1.01-1.03). Conclusions: Despite improved survival with monoclonal antibody therapy, our findings highlight a high incidence of neurologic sequelae in the REGN-EB3 group and musculoskeletal sequelae in the ZMapp group as compared with the remdesivir group, as well as among older survivors, women, and those with comorbidities. These results underscore the need for targeting long-term care to effectively manage post-Ebola sequelae.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.